Premium
Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add‐on study from the Groupe Francophone des Myelodysplasies
Author(s) -
Prebet Thomas,
Delaunay Jacques,
Wattel Eric,
Braun Thorsten,
ConyMakhoul Pascale,
Dimicoli Sophie,
Wickenhauser Stephan,
Lejeune Julie,
Chevret Sylvie,
Chermat Fatiha,
Fenaux Pierre,
Vey Norbert
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14427
Subject(s) - azacitidine , myelodysplastic syndromes , vorinostat , medicine , oncology , biology , dna methylation , genetics , histone , bone marrow , gene expression , histone deacetylase , gene